{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T17:06:01Z","timestamp":1779728761147,"version":"3.53.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021772","name":"Deanship of Scientific Research, University of Jordan","doi-asserted-by":"crossref","award":["20200404\/20200656"],"award-info":[{"award-number":["20200404\/20200656"]}],"id":[{"id":"10.13039\/501100021772","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"DOI":"10.1007\/s10822-026-00806-5","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:47:05Z","timestamp":1779727625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hit-to-lead optimization of heteroaryl amino-carboxamides as LSD1 inhibitors: part II"],"prefix":"10.1007","volume":"40","author":[{"given":"Dalia","family":"Ammar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-8802","authenticated-orcid":false,"given":"Soraya","family":"Alnabulsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufaida","family":"Al Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"806_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/B978-0-12-405944-3.00009-X","volume-title":"Transgenerational Epigenetics","author":"J Li","year":"2014","unstructured":"Li J, Ding Y, Zheng L (2014) Chapter 9 - Histone-Mediated Transgenerational Epigenetics. In: Tollefsbol T (ed) Transgenerational Epigenetics. Academic Press, Oxford, pp 87\u2013103"},{"issue":"7","key":"806_CR2","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7):941\u2013953. https:\/\/doi.org\/10.1016\/j.cell.2004.12.012","journal-title":"Cell"},{"key":"806_CR3","doi-asserted-by":"publisher","DOI":"10.1615\/critreveukargeneexpr.v22.i1.40","author":"Y Chen","year":"2012","unstructured":"Chen Y, Jie W, Yan W, Zhou K, Xiao Y (2012) Lysine-specific histone demethylase 1 (LSD1): a potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr. https:\/\/doi.org\/10.1615\/critreveukargeneexpr.v22.i1.40","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"5","key":"806_CR4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/med.21350","volume":"35","author":"Y-C Zheng","year":"2015","unstructured":"Zheng Y-C, Ma J, Wang Z, Li J, Jiang B, Zhou W et al (2015) A systematic review of histone lysine-specific demethylase 1 and its inhibitors. Med Res Rev 35(5):1032\u20131071. https:\/\/doi.org\/10.1002\/med.21350","journal-title":"Med Res Rev"},{"issue":"8","key":"806_CR5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2217\/epi-2017-0022","volume":"9","author":"A Hosseini","year":"2017","unstructured":"Hosseini A, Minucci S (2017) A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Epigenomics 9(8):1123\u20131142. https:\/\/doi.org\/10.2217\/epi-2017-0022","journal-title":"Epigenomics"},{"issue":"9","key":"806_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/cas.13004","volume":"107","author":"S Hino","year":"2016","unstructured":"Hino S, Kohrogi K, Nakao M (2016) Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. Cancer Sci 107(9):1187\u20131192","journal-title":"Cancer Sci"},{"issue":"3","key":"806_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/cancers11030324","volume":"11","author":"B Majello","year":"2019","unstructured":"Majello B, Gorini F, Sacc\u00e0 CD, Amente S (2019) Expanding the role of the histone lysine-specific demethylase LSD1 in cancer. Cancers 11(3):324","journal-title":"Cancers"},{"issue":"2","key":"806_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2014.02.013","volume":"347","author":"Y Qin","year":"2014","unstructured":"Qin Y, Zhu W, Xu W, Zhang B, Shi S, Ji S et al (2014) LSD1 sustains pancreatic cancer growth via maintaining HIF1\u03b1-dependent glycolytic process. Cancer Lett 347(2):225\u2013232","journal-title":"Cancer Lett"},{"issue":"1","key":"806_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13277-012-0525-x","volume":"34","author":"Z-K Zhao","year":"2013","unstructured":"Zhao Z-K, Dong P, Gu J, Chen L, Zhuang M, Lu W-J et al (2013) Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma. Tumor Biol 34(1):173\u2013180","journal-title":"Tumor Biol"},{"issue":"5","key":"806_CR10","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/0008-5472.CAN-08-1735","volume":"69","author":"JH Schulte","year":"2009","unstructured":"Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R et al (2009) Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69(5):2065\u20132071. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1735","journal-title":"Cancer Res"},{"issue":"4","key":"806_CR11","doi-asserted-by":"publisher","first-page":"e35065","DOI":"10.1371\/journal.pone.0035065","volume":"7","author":"T Lv","year":"2012","unstructured":"Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X et al (2012) Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS ONE 7(4):e35065","journal-title":"PLoS ONE"},{"issue":"3","key":"806_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/carcin\/bgp324","volume":"31","author":"S Lim","year":"2010","unstructured":"Lim S, Janzer A, Becker A, Zimmer A, Sch\u00fcle R, Buettner R et al (2010) Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31(3):512\u2013520","journal-title":"Carcinogenesis"},{"issue":"23","key":"806_CR13","doi-asserted-by":"publisher","first-page":"11341","DOI":"10.1158\/0008-5472.CAN-06-1570","volume":"66","author":"P Kahl","year":"2006","unstructured":"Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R et al (2006) Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Can Res 66(23):11341\u201311347","journal-title":"Can Res"},{"issue":"3","key":"806_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ijc.25349","volume":"128","author":"S Hayami","year":"2011","unstructured":"Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T et al (2011) Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128(3):574\u2013586","journal-title":"Int J Cancer"},{"issue":"11","key":"806_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.4155\/fmc-2017-0068","volume":"9","author":"X Fu","year":"2017","unstructured":"Fu X, Zhang P, Yu B (2017) Advances toward LSD1 inhibitors for cancer therapy. Future Med Chem 9(11):1227\u20131242. https:\/\/doi.org\/10.4155\/fmc-2017-0068","journal-title":"Future Med Chem"},{"key":"806_CR16","first-page":"2565","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Hu L, Du Y, Kong F, Pan Y (2015) Prognostic role of LSD1 in various cancers: evidence from a meta-analysis. OncoTargets Therapy 8:2565","journal-title":"OncoTargets Therapy"},{"key":"806_CR17","doi-asserted-by":"publisher","first-page":"112243","DOI":"10.1016\/j.ejmech.2020.112243","volume":"194","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang C, Zhang X, Yan J, Wang J, Jiang Q et al (2020) Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors. Eur J Med Chem 194:112243. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112243","journal-title":"Eur J Med Chem"},{"issue":"5","key":"806_CR18","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1021\/acs.jmedchem.6b01019","volume":"60","author":"P Vianello","year":"2017","unstructured":"Vianello P, Sartori L, Amigoni F, Cappa A, Fag\u00e1 G, Fattori R et al (2017) Thieno [3,2-b]pyrrole-5-carboxamides as new reversible inhibitors of histone lysine demethylase KDM1A\/LSD1. Part 2: Structure-based drug design and structure\u2013activity relationship. J Med Chem 60(5):1693\u20131715","journal-title":"J Med Chem"},{"issue":"5","key":"806_CR19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1021\/acs.jmedchem.6b01018","volume":"60","author":"L Sartori","year":"2017","unstructured":"Sartori L, Mercurio C, Amigoni F, Cappa A, Fag\u00e1 G, Fattori R et al (2017) Thieno [3,2-b]pyrrole-5-carboxamides as new reversible inhibitors of histone lysine demethylase KDM1A\/LSD1. Part 1: high-throughput screening and preliminary exploration. J Med Chem 60(5):1673\u20131692","journal-title":"J Med Chem"},{"issue":"4","key":"806_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.bmcl.2018.12.067","volume":"29","author":"L Li","year":"2019","unstructured":"Li L, Li R, Wang Y (2019) Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking. Bioorg Med Chem Lett 29(4):544\u2013548. https:\/\/doi.org\/10.1016\/j.bmcl.2018.12.067","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"806_CR21","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1021\/acs.jmedchem.1c02156","volume":"65","author":"C Li","year":"2022","unstructured":"Li C, Su M, Zhu W, Kan W, Ge T, Xu G et al (2022) Structure-activity relationship study of Indolin-5-yl-cyclopropanamine derivatives as selective lysine specific demethylase 1 (LSD1) inhibitors. J Med Chem 65(5):4335\u20134349. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02156","journal-title":"J Med Chem"},{"issue":"23","key":"806_CR22","doi-asserted-by":"publisher","first-page":"14522","DOI":"10.1021\/acs.jmedchem.0c00978","volume":"63","author":"T Kanouni","year":"2020","unstructured":"Kanouni T, Severin C, Cho RW, Yuen NYY, Xu J, Shi L et al (2020) Discovery of CC-90011: a potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1). J Med Chem 63(23):14522\u201314529. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00978","journal-title":"J Med Chem"},{"issue":"6","key":"806_CR23","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1021\/acs.jmedchem.2c01593","volume":"66","author":"X-J Dai","year":"2023","unstructured":"Dai X-J, Zhao L-J, Yang L-H, Guo T, Xue L-P, Ren H-M et al (2023) Phenothiazine-based LSD1 inhibitor promotes T-cell killing response of gastric cancer cells. J Med Chem 66(6):3896\u20133916. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01593","journal-title":"J Med Chem"},{"issue":"5","key":"806_CR24","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1021\/acs.jmedchem.0c02176","volume":"64","author":"X-J Dai","year":"2021","unstructured":"Dai X-J, Liu Y, Xue L-P, Xiong X-P, Zhou Y, Zheng Y-C et al (2021) Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1. J Med Chem 64(5):2466\u20132488. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c02176","journal-title":"J Med Chem"},{"issue":"23","key":"806_CR25","doi-asserted-by":"publisher","first-page":"14197","DOI":"10.1021\/acs.jmedchem.0c00919","volume":"63","author":"X-J Dai","year":"2020","unstructured":"Dai X-J, Liu Y, Xiong X-P, Xue L-P, Zheng Y-C, Liu H-M (2020) Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective. J Med Chem 63(23):14197\u201314215. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00919","journal-title":"J Med Chem"},{"issue":"8","key":"806_CR26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2217\/epi-2016-0009","volume":"8","author":"A Maiques-Diaz","year":"2016","unstructured":"Maiques-Diaz A, Somervaille TCP (2016) LSD1: biologic roles and therapeutic targeting. Epigenomics 8(8):1103\u20131116. https:\/\/doi.org\/10.2217\/epi-2016-0009","journal-title":"Epigenomics"},{"key":"806_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1120911","author":"B Noce","year":"2023","unstructured":"Noce B, Di Bello E, Fioravanti R, Mai A (2023) LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1120911","journal-title":"Front Pharmacol"},{"key":"806_CR28","unstructured":"A Phase 1 Dose Escalation Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Relapsed\/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) [database on the Internet] 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02273102. Accessed:"},{"key":"806_CR29","unstructured":"A Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination With Azacitidine and Venetoclax in Newly Diagnosed AML [database on the Internet] 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06357182. Accessed:"},{"key":"806_CR30","unstructured":"A Phase 2 Study of Iadademstat in Combination With Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas [database on the Internet] 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05420636. Accessed:"},{"key":"806_CR31","unstructured":"A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV) [database on the Internet] 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05558696. Accessed:"},{"key":"806_CR32","unstructured":"A Phase I\/II Study of Bomedemstat Combined With Maintenance Immunotherapy for Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) [database on the Internet] 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05191797. Accessed:"},{"key":"806_CR33","unstructured":"A First-in-Human, Open-label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients With Advanced Solid Tumors [database on the Internet] 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05268666. Accessed:"},{"issue":"48","key":"806_CR34","doi-asserted-by":"publisher","first-page":"17536","DOI":"10.1021\/ja907055q","volume":"131","author":"R Ueda","year":"2009","unstructured":"Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M et al (2009) Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 131(48):17536\u201317537. https:\/\/doi.org\/10.1021\/ja907055q","journal-title":"J Am Chem Soc"},{"issue":"2","key":"806_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1535-7163.MCT-16-0471","volume":"16","author":"Y Ishikawa","year":"2017","unstructured":"Ishikawa Y, Gamo K, Yabuki M, Takagi S, Toyoshima K, Nakayama K et al (2017) A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cells. Mol Cancer Ther 16(2):273\u2013284","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"806_CR36","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1021\/jm401002r","volume":"56","author":"Y-C Zheng","year":"2013","unstructured":"Zheng Y-C, Duan Y-C, Ma J-L, Xu R-M, Zi X, Lv W-L et al (2013) Triazole-Dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. J Med Chem 56(21):8543\u20138560. https:\/\/doi.org\/10.1021\/jm401002r","journal-title":"J Med Chem"},{"key":"806_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105958","volume":"175","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wang X, Wu T, Yin W, Yan J, Sun Y et al (2022) Therapeutic potential of targeting LSD1\/KDM1A in cancers. Pharmacol Res 175:105958. https:\/\/doi.org\/10.1016\/j.phrs.2021.105958","journal-title":"Pharmacol Res"},{"key":"806_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejmech.2016.04.024","volume":"117","author":"B Yu","year":"2016","unstructured":"Yu B, Qi P-P, Shi X-J, Huang R, Guo H, Zheng Y-C et al (2016) Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach. Eur J Med Chem 117:241\u2013255. https:\/\/doi.org\/10.1016\/j.ejmech.2016.04.024","journal-title":"Eur J Med Chem"},{"issue":"1","key":"806_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1021\/acs.jmedchem.5b01361","volume":"59","author":"F Wu","year":"2016","unstructured":"Wu F, Zhou C, Yao Y, Wei L, Feng Z, Deng L et al (2016) 3-(Piperidin-4-ylmethoxy)pyridine containing compounds are potent inhibitors of lysine specific demethylase 1. J Med Chem 59(1):253\u2013263. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01361","journal-title":"J Med Chem"},{"issue":"23","key":"806_CR40","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1158\/0008-5472.CAN-11-0896","volume":"71","author":"J Wang","year":"2011","unstructured":"Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R et al (2011) Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Can Res 71(23):7238\u20137249","journal-title":"Can Res"},{"issue":"11","key":"806_CR41","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1039\/c3md00226h","volume":"4","author":"JR Hitchin","year":"2013","unstructured":"Hitchin JR, Blagg J, Burke R, Burns S, Cockerill MJ, Fairweather EE et al (2013) Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments. MedChemComm 4(11):1513\u20131522","journal-title":"MedChemComm"},{"issue":"19","key":"806_CR42","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1039\/c3ob40217g","volume":"11","author":"B Dulla","year":"2013","unstructured":"Dulla B, Kirla KT, Rathore V, Deora GS, Kavela S, Maddika S et al (2013) Synthesis and evaluation of 3-amino\/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties. Org Biomol Chem 11(19):3103\u20133107","journal-title":"Org Biomol Chem"},{"key":"806_CR43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejmech.2016.11.035","volume":"126","author":"Y-C Duan","year":"2017","unstructured":"Duan Y-C, Guan Y-Y, Zhai X-Y, Ding L-N, Qin W-P, Shen D-D et al (2017) Discovery of resveratrol derivatives as novel LSD1 inhibitors: design, synthesis and their biological evaluation. Eur J Med Chem 126:246\u2013258. https:\/\/doi.org\/10.1016\/j.ejmech.2016.11.035","journal-title":"Eur J Med Chem"},{"issue":"10","key":"806_CR44","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1021\/acsmedchemlett.3c00292","volume":"14","author":"C Zheng","year":"2023","unstructured":"Zheng C, Rej RK, Wang M, Huang L, Fernandez-Salas E, Yang C-Y et al (2023) Discovery of Pyrrolo[2,3-c]pyridines as potent and reversible LSD1 inhibitors. ACS Med Chem Lett 14(10):1389\u20131395. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00292","journal-title":"ACS Med Chem Lett"},{"key":"806_CR45","unstructured":"A Phase 2, Multicenter, Open-label, Multi-cohort Study to Assess Safety and Efficacy of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers [database on the Internet]2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04350463. Accessed:"},{"key":"806_CR46","unstructured":"A Phase 1b, Multicenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of CC-90011 Given in Combination With Cisplatin and Etoposide in First Line, Extensive Stage Subjects With Small Cell Lung Cancer [database on the Internet] 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03850067. Accessed:"},{"issue":"15_suppl","key":"806_CR47","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1200\/JCO.2021.39.15_suppl.11514","volume":"39","author":"DR Reed","year":"2021","unstructured":"Reed DR, Chawla SP, Setty B, Mascarenhas L, Meyers PA, Metts J et al (2021) Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed\/refractory Ewing sarcoma. J Clin Oncol 39(15_suppl):11514. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.11514","journal-title":"J Clin Oncol"},{"key":"806_CR48","unstructured":"Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors [database on the Internet] 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03895684. Accessed:"},{"key":"806_CR49","unstructured":"Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas [database on the Internet] 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03600649. Accessed:"},{"key":"806_CR50","doi-asserted-by":"publisher","first-page":"107440","DOI":"10.1016\/j.jmgm.2019.107440","volume":"93","author":"S Alnabulsi","year":"2019","unstructured":"Alnabulsi S, Al-Hurani EA, Al-Shar\u2019i NA, El-Elimat T (2019) Amino-carboxamide benzothiazoles as potential LSD1 hit inhibitors. Part I: computational fragment-based drug design. J Mol Graph Model 93:107440. https:\/\/doi.org\/10.1016\/j.jmgm.2019.107440","journal-title":"J Mol Graph Model"},{"issue":"5","key":"806_CR51","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00044-023-03046-6","volume":"32","author":"D Al bustanji","year":"2023","unstructured":"Al bustanji D, Alnabulsi S, Al-Hurani EA (2023) Hit-to-lead optimization of amino-carboxamide benzothiazoles as LSD1 inhibitors. Med Chem Res 32(5):910\u2013929. https:\/\/doi.org\/10.1007\/s00044-023-03046-6","journal-title":"Med Chem Res"},{"issue":"9","key":"806_CR52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/10426507.2020.1756808","volume":"195","author":"L Yurtta\u015f","year":"2020","unstructured":"Yurtta\u015f L, Kubilay A, Evren AE, K\u0131sac\u0131k \u0130, Karaca Gen\u00e7er H (2020) Synthesis of some novel 3,4,5-trisubstituted triazole derivatives bearing quinoline ring and evaluation of their antimicrobial activity. Phosphorus Sulfur Silicon Relat Elem 195(9):767\u2013773. https:\/\/doi.org\/10.1080\/10426507.2020.1756808","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"key":"806_CR53","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ejmech.2018.09.003","volume":"158","author":"T Iida","year":"2018","unstructured":"Iida T, Ubukata M, Mitani I, Nakagawa Y, Maeda K, Imai H et al (2018) Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity. Eur J Med Chem 158:832\u2013852. https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.003","journal-title":"Eur J Med Chem"},{"issue":"6","key":"806_CR54","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cclet.2008.03.027","volume":"19","author":"S Rostamizadeh","year":"2008","unstructured":"Rostamizadeh S, Ghamkhar S (2008) A mild and facile method for one pot synthesis of 2,5-di-substituted 1,3,4-oxadiazoles at room temperature. Chin Chem Lett 19(6):639\u2013642. https:\/\/doi.org\/10.1016\/j.cclet.2008.03.027","journal-title":"Chin Chem Lett"},{"issue":"11","key":"806_CR55","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00706-009-0186-7","volume":"140","author":"RM Srivastava","year":"2009","unstructured":"Srivastava RM, Pereira MC, Faustino WWM, Coutinho K, dos Anjos JV, de Melo SJ (2009) Synthesis, mechanism of formation, and molecular orbital calculations of arylamidoximes. Monatsh Chem 140(11):1319. https:\/\/doi.org\/10.1007\/s00706-009-0186-7","journal-title":"Monatsh Chem"},{"issue":"21","key":"806_CR56","doi-asserted-by":"publisher","first-page":"8373","DOI":"10.1021\/acs.jmedchem.5b01275","volume":"58","author":"MT Burger","year":"2015","unstructured":"Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G et al (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a potent and selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 kinase inhibitor in clinical trials for hematological malignancies. J Med Chem 58(21):8373\u20138386. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01275","journal-title":"J Med Chem"},{"issue":"2","key":"806_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1021\/ct100578z","volume":"7","author":"MHM Olsson","year":"2011","unstructured":"Olsson MHM, S\u00f8ndergaard CR, Rostkowski M, Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput 7(2):525\u2013537. https:\/\/doi.org\/10.1021\/ct100578z","journal-title":"J Chem Theory Comput"},{"issue":"3","key":"806_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"G Madhavi Sastry","year":"2013","unstructured":"Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27(3):221\u2013234. https:\/\/doi.org\/10.1007\/s10822-013-9644-8","journal-title":"J Comput Aided Mol Des"},{"issue":"12","key":"806_CR59","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M (2007) Epik: a software program for pKaprediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21(12):681\u2013691. https:\/\/doi.org\/10.1007\/s10822-007-9133-z","journal-title":"J Comput Aided Mol Des"},{"issue":"2","key":"806_CR60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/jm050540c","volume":"49","author":"W Sherman","year":"2006","unstructured":"Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand\/receptor Induced Fit effects. J Med Chem 49(2):534\u2013553. https:\/\/doi.org\/10.1021\/jm050540c","journal-title":"J Med Chem"},{"issue":"7","key":"806_CR61","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750\u20131759. https:\/\/doi.org\/10.1021\/jm030644s","journal-title":"J Med Chem"},{"issue":"7","key":"806_CR62","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47(7):1739\u20131749. https:\/\/doi.org\/10.1021\/jm0306430","journal-title":"J Med Chem"},{"issue":"17","key":"806_CR63","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1021\/jm3002845","volume":"55","author":"S Hazeldine","year":"2012","unstructured":"Hazeldine S, Pachaiyappan B, Steinbergs N, Nowotarski S, Hanson AS, Casero RA et al (2012) Low molecular weight amidoximes that act as potent inhibitors of Lysine-Specific Demethylase 1. J Med Chem 55(17):7378\u20137391. https:\/\/doi.org\/10.1021\/jm3002845","journal-title":"J Med Chem"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00806-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:47:08Z","timestamp":1779727628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00806-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00806-5","relation":{},"ISSN":["1573-4951"],"issn-type":[{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"130"}}